Figure 2.
Time to treatment failure according to drug class of 36 molecular targeted treatments in 30 patients. Index date is the starting date of treatment. Six patients were censored (+), four being on-treatment and two pausing treatment without progression. SMI includes four patients treated with PARPi. HER2, human epidermal growth factor receptor 2; ICI, immune check point inhibitor; PARPi, poly-ADP-ribose-polymerase inhibitor; SMI, small-molecule inhibitor.
